Theravance Biopharma (TBPH) has received a new Buy rating, initiated by JonesTrading analyst, Debanjana Chatterjee.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Debanjana Chatterjee has given her Buy rating due to a combination of factors related to the treatment landscape for neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) patients. The current treatment options are inadequate for a significant portion of patients, with many experiencing insufficient control or developing treatment-limiting side effects like supine hypertension.
Chatterjee highlights that there is a strong demand among key opinion leaders (KOLs) for a once-daily treatment option that offers improved safety and effectiveness. The potential for ampreloxetine to be prescribed to nearly all MSA patients with nOH, as indicated by KOLs, suggests a promising market opportunity for Theravance Biopharma. This unmet need and the positive outlook for ampreloxetine’s adoption underpin the Buy rating for the company’s stock.
Chatterjee covers the Healthcare sector, focusing on stocks such as Tvardi Therapeutics, Opus Genetics, and KalVista Pharmaceuticals. According to TipRanks, Chatterjee has an average return of 11.3% and a 50.82% success rate on recommended stocks.
In another report released on June 2, BTIG also maintained a Buy rating on the stock with a $24.00 price target.